Daesung Microbiological Labs. Co. Ltd - Asset Resilience Ratio
Daesung Microbiological Labs. Co. Ltd (036480) has an Asset Resilience Ratio of 10.25% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Daesung Microbiological Labs. Co. Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Daesung Microbiological Labs. Co. Ltd's Asset Resilience Ratio has changed over time. See how leveraged is Daesung Microbiological Labs. Co. Ltd's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Daesung Microbiological Labs. Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Daesung Microbiological Labs. Co. Ltd (036480) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩5.94 Billion | 10.25% |
| Total Liquid Assets | ₩5.94 Billion | 10.25% |
Asset Resilience Insights
- Moderate Liquidity: Daesung Microbiological Labs. Co. Ltd has 10.25% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Daesung Microbiological Labs. Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Daesung Microbiological Labs. Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Daesung Microbiological Labs. Co. Ltd (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Daesung Microbiological Labs. Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.25% | ₩5.94 Billion ≈ $4.03 Million |
₩57.98 Billion ≈ $39.29 Million |
-5.26pp |
| 2024-12-31 | 15.51% | ₩9.05 Billion ≈ $6.14 Million |
₩58.38 Billion ≈ $39.56 Million |
-2.73pp |
| 2023-12-31 | 18.24% | ₩11.73 Billion ≈ $7.95 Million |
₩64.29 Billion ≈ $43.57 Million |
-1.51pp |
| 2022-12-31 | 19.75% | ₩12.86 Billion ≈ $8.71 Million |
₩65.11 Billion ≈ $44.12 Million |
+3.88pp |
| 2021-12-31 | 15.86% | ₩9.93 Billion ≈ $6.73 Million |
₩62.62 Billion ≈ $42.44 Million |
-0.28pp |
| 2020-12-31 | 16.14% | ₩10.05 Billion ≈ $6.81 Million |
₩62.26 Billion ≈ $42.19 Million |
-8.49pp |
| 2019-12-31 | 24.63% | ₩12.50 Billion ≈ $8.47 Million |
₩50.77 Billion ≈ $34.40 Million |
-4.70pp |
| 2018-12-31 | 29.33% | ₩11.17 Billion ≈ $7.57 Million |
₩38.10 Billion ≈ $25.82 Million |
+2.98pp |
| 2017-12-31 | 26.35% | ₩9.17 Billion ≈ $6.21 Million |
₩34.78 Billion ≈ $23.57 Million |
-1.44pp |
| 2016-12-31 | 27.79% | ₩9.90 Billion ≈ $6.71 Million |
₩35.61 Billion ≈ $24.13 Million |
+22.98pp |
| 2015-12-31 | 4.82% | ₩1.56 Billion ≈ $1.06 Million |
₩32.42 Billion ≈ $21.97 Million |
+1.02pp |
| 2014-12-31 | 3.79% | ₩1.05 Billion ≈ $714.28K |
₩27.79 Billion ≈ $18.83 Million |
+0.37pp |
| 2013-12-31 | 3.42% | ₩990.00 Million ≈ $670.91K |
₩28.95 Billion ≈ $19.62 Million |
-0.74pp |
| 2012-12-31 | 4.16% | ₩1.06 Billion ≈ $719.02K |
₩25.49 Billion ≈ $17.28 Million |
-- |
About Daesung Microbiological Labs. Co. Ltd
Daesung Microbiological Labs. Co., Ltd. manufactures and sells vaccines for swine, poultry, canine, cattle, and fish in South Korea. It offers antibiotics and antibacterials, parasiticides and disinfectants, probiotics and enzyme products, and nutrients and pharmaceuticals. The company also exports its products. Daesung Microbiological Labs. Co., Ltd. was founded in 1966 and is headquartered in U… Read more